VEGFA and cancer: Indeed, a recent meta-analysis [22] including 24 randomized trials with 8 different types of cancers, in which the synthetic antagonist of VEGF (Bevacizumab®;) was used in combination with chemotherapy, shown a statistically significant improvement in the overall survival and progression of free cancer survival in patients who received Bevacizumab®; compared with those who did not receive this drug.